Biological Factors – Page 2

Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand

3 months ago talkbio0Tagged Biological Factors, CDMO, Cells, gene therapy, Industry, Leadership, Lonza, pharmaceutical manufacturing, Small Molecule, Wolfgang Wienand

Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

3 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

4 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

4 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

5 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

5 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)